Breast Cancer Clinical Trial

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

Summary

The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate cancer (mCRPC) stage.

View Full Description

Full Description

PROpel is a phase III study evaluating the efficacy, safety, and tolerability of olaparib versus placebo when given in addition to abiraterone to patients with metastatic castration-resistant prostate cancer (mCRPC) who have not received prior chemotherapy or new hormonal agents (NHAs) for metastatic castration-resistant prostate cancer (mCRPC) (first-line setting).

Approximately 720 patients globally were planned to be randomized in PROpel in a 1:1 ratio to treatment with either olaparib and abiraterone or placebo and abiraterone. Enrolment had completed with a total of 796 patients randomised. Following the completion of global enrolment, the China cohort will randomise approximately 108 additional patients at sites in China, also in a 1:1 ratio.

Patients will receive oral treatment with olaparib 300 mg twice daily + abiraterone 1000 mg once daily or placebo twice daily + abiraterone 1000 mg once daily. Patients in both treatment groups will also receive either prednisone or prednisolone 5 mg twice daily.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form and in the study protocol.
Provision of signed and dated, written informed consent form prior to any mandatory study specific procedures, sampling, and analyses.

For inclusion in i) the optional exploratory genetic research and ii) the optional biomarker research, patients must fulfill the following criteria:

Provision of informed consent for genetic research prior to collection of sample.
Provision of informed consent for biomarker research prior to collection of sample.

If a patient declines to participate in the optional exploratory genetic research or the optional biomarker research, there will be no penalty or loss of benefit to the patient. The patient will not be excluded from other aspects of the study.

Patients must be ≥18 years of age (or ≥19 years of age in South Korea) at the time of signing the informed consent form. For patients enrolled in Japan who are <20 years of age, written informed consent should be obtained from the patient and from his legally acceptable representative.
Histologically or cytologically confirmed prostate adenocarcinoma.
Metastatic status defined as at least 1 documented metastatic lesion on either a bone scan or a computed tomography(CT)/ magnetic resonance imaging (MRI) scan.
First-line metastatic castration-resistant prostate cancer (mCRPC).
Ongoing androgen deprivation with gonadotropin-releasing hormone analogue or bilateral orchiectomy, with serum testosterone <50 nanograms per decilitre (ng/dL) (<2.0 nanomoles per litre (nmol/L)) within 28 days before randomisation. Patients receiving androgen deprivation therapy (ADT) at study entry should continue to do so throughout the study.
Candidate for abiraterone therapy with documented evidence of progressive disease.
Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment.
Eastern Cooperative Oncology Group (ECOG) performance status 0-1, with no deterioration over the previous 2 weeks.
The participant has, in the opinion of the investigator, a life expectancy of at least 6 months.
Prior to randomisation, sites must confirm availability of either an archival formalin fixed, paraffin embedded (FFPE) tumour tissue sample, or a new biopsy taken during the screening window, which meets the minimum pathology and sample requirements in order to enable homologous recombination repair (HRR) status subgroup analysis of the primary endpoint radiographic progression-free survival (rPFS). If there is not written confirmation of the availability of tumour tissue prior to randomisation, the patient is not eligible for the study.
Male patients must use a condom during treatment and for 3 months after the last dose of olaparib+abiraterone when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male patients should also use a highly effective form of contraception if they are of childbearing potential.

Exclusion Criteria:

Has a known additional malignancy that has had progression or has required active treatment in the last 5 years.
Patients with myelodysplastic syndrome (MDS)/ acute myeloid leukaemia (AML) or with features suggestive of yelodysplastic syndrome (MDS)/ acute myeloid leukaemia (AML).
Clinically significant cardiovascular disease Association Class II-IV heart failure or cardiac ejection fraction measurement of <50% during screening as assessed by echocardiography or multigated acquisition scan.
Planned or scheduled cardiac surgery or percutaneous coronary intervention procedure.
Prior revascularisation procedure (significant coronary, carotid, or peripheral artery stenosis).
Uncontrolled hypertension (systolic blood pressure (BP) ≥160 millimeters of mercury (mmHg) or diastolic blood pressure (BP) ≥95 millimeters of mercury (mmHg)).
History of uncontrolled pituitary or adrenal dysfunction.
Active infection or other medical condition that would make prednisone/prednisolone use contraindicated.
Any chronic medical condition requiring a systemic dose of corticosteroid >10 milligrams (mg) prednisone/prednisolone per day.
Patients who are considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection.
Persistent toxicities (Common Terminology Criteria for Adverse Events [CTCAEs] grade >2) caused by previous cancer therapy, excluding alopecia.
Patients with brain metastases. A scan to confirm the absence of brain metastases is not required.
Patients with spinal cord compression are excluded unless they are considered to have received definitive treatment for this and have evidence of clinically stable disease for 4 weeks.
Patients who are unevaluable for both bone and soft tissue progression
Patients who are unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
Immunocompromised patients
Patients with known active hepatitis infection (ie, hepatitis B or C).
Any previous treatment with Polyadenosine 5'diphosphoribose [poly (ADP ribose)] polymerase (PARP) inhibitor, including olaparib.
Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment. Patients who receive palliative radiotherapy need to stop radiotherapy 1 week before randomisation.
Any previous exposure to a Cytochrome P450 (CYP) 17 (17α-hydroxylase/C17,20-lyase) inhibitor (eg, abiraterone, orteronel).
Concomitant use of known strong Cytochrome P450 (CYP) 3A inhibitors (eg, itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg, ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting study treatment is 2 weeks.
Concomitant use of known strong Cytochrome P450 (CYP) 3A inducers (eg, phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine or St John's wort) or moderate Cytochrome P450 (CYP) 3A inducers (eg, bosentan, efavirenz or modafinil). The required period prior to starting study treatment is 5 weeks for phenobarbital and enzalutamide and 3 weeks for other agents.
Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.
Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT).
Participation in another clinical study with an investigational product or investigational medical devices within 1 month of randomisation.
History of hypersensitivity to olaparib or abiraterone, any of the excipients of olaparib or abiraterone, or drugs with a similar chemical structure or class to olaparib or abiraterone.
Involvement in the planning and/or conduct of the study (applies to both AstraZeneca and Merck staff and/or staff at the study site).
Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.
Previous randomisation in the present study.

Study is for people with:

Breast Cancer

Phase:

Phase 3

Estimated Enrollment:

895

Study ID:

NCT03732820

Recruitment Status:

Active, not recruiting

Sponsor:

AstraZeneca

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 132 Locations for this study

See Locations Near You

Research Site
Birmingham Alabama, 35209, United States
Research Site
Anchorage Alaska, 99503, United States
Research Site
Tucson Arizona, 85704, United States
Research Site
Tucson Arizona, 85741, United States
Research Site
Clovis California, 93611, United States
Research Site
Los Angeles California, 90027, United States
Research Site
Los Angeles California, 90073, United States
Research Site
Sacramento California, 95817, United States
Research Site
San Diego California, 92123, United States
Research Site
Denver Colorado, 80211, United States
Research Site
Lisle Illinois, 60532, United States
Research Site
Jeffersonville Indiana, 47130, United States
Research Site
New Orleans Louisiana, 70112, United States
Research Site
Detroit Michigan, 48202, United States
Research Site
Grand Rapids Michigan, 49503, United States
Research Site
Saint Louis Missouri, 63106, United States
Research Site
Bozeman Montana, 59715, United States
Research Site
Omaha Nebraska, 68130, United States
Research Site
Paramus New Jersey, 07652, United States
Research Site
Brooklyn New York, 11220, United States
Research Site
New Hyde Park New York, 11042, United States
Research Site
Rochester New York, 14642, United States
Research Site
Syracuse New York, 13210, United States
Research Site
Durham North Carolina, 27710, United States
Research Site
Philadelphia Pennsylvania, 19111, United States
Research Site
Charleston South Carolina, 29425, United States
Research Site
Myrtle Beach South Carolina, 29572, United States
Research Site
Milwaukee Wisconsin, 53226, United States
Research Site
Box Hill , 3128, Australia
Research Site
Darlinghurst , 2010, Australia
Research Site
Greenslopes , 4120, Australia
Research Site
Herston , 4029, Australia
Research Site
Kingswood , 2747, Australia
Research Site
Kurralta Park , 5037, Australia
Research Site
St Albans , 3021, Australia
Research Site
Waratah , 2298, Australia
Research Site
Gent , 9000, Belgium
Research Site
Belo Horizonte , 30110, Brazil
Research Site
Curitiba , 80810, Brazil
Research Site
Fortaleza , 60336, Brazil
Research Site
Porto Alegre , 91350, Brazil
Research Site
Rio de Janeiro , 22793, Brazil
Research Site
Sao Paulo , 01221, Brazil
Research Site
Sao Paulo , 04266, Brazil
Research Site
São José do Rio Preto , 15090, Brazil
Research Site
Calgary Alberta, T2V 1, Canada
Research Site
Edmonton Alberta, T6G 1, Canada
Research Site
Kelowna British Columbia, V1Y 5, Canada
Research Site
Halifax Nova Scotia, B3H 1, Canada
Research Site
London Ontario, N6A 5, Canada
Research Site
Toronto Ontario, M4N 3, Canada
Research Site
Toronto Ontario, M5G 2, Canada
Research Site
Greenfield Park Quebec, J4V 2, Canada
Research Site
Montreal Quebec, H2X 3, Canada
Research Site
Montreal Quebec, H3T 1, Canada
Research Site
Santiago , 75007, Chile
Research Site
Santiago , 75203, Chile
Research Site
Temuco , 47811, Chile
Research Site
Viña del Mar , 25404, Chile
Research Site
Brno , 656 5, Czechia
Research Site
Praha 5 , 150 0, Czechia
Research Site
Praha , 120 0, Czechia
Research Site
Praha , 140 5, Czechia
Research Site
Angers Cedex 01 , 49033, France
Research Site
BESANCON Cedex , 25030, France
Research Site
Caen Cedex 05 , 14076, France
Research Site
Pierre Benite , 69495, France
Research Site
Quimper Cedex , 29107, France
Research Site
Vandoeuvre les Nancy , 54519, France
Research Site
Bergisch Gladbach , 51465, Germany
Research Site
Bremen , 28277, Germany
Research Site
Duisburg , 47169, Germany
Research Site
Freiburg im Breisgau , 79106, Germany
Research Site
Heinsberg , 52525, Germany
Research Site
Köln , 50968, Germany
Research Site
Mettmann , 40822, Germany
Research Site
Nürnberg , 90419, Germany
Research Site
Nürtingen , 72622, Germany
Research Site
Ulm , 89081, Germany
Research Site
Milano , 20133, Italy
Research Site
Milano , 20141, Italy
Research Site
Napoli , 80131, Italy
Research Site
Orbassano , 10043, Italy
Research Site
Pavia , 27100, Italy
Research Site
Bunkyo-ku , 113-8, Japan
Research Site
Hirakata-shi , 573-1, Japan
Research Site
Kanazawa-shi , 920-8, Japan
Research Site
Kashihara-shi , 634-8, Japan
Research Site
Kawagoe-shi , 350-8, Japan
Research Site
Kita-gun , 761-0, Japan
Research Site
Kyoto-shi , 606-8, Japan
Research Site
Maebashi-shi , 371-8, Japan
Research Site
Miyazaki-city , 889-1, Japan
Research Site
Nagoya-shi , 466-8, Japan
Research Site
Osaka-shi , 541-8, Japan
Research Site
Osaka-shi , 545-8, Japan
Research Site
Osakasayama-shi , 589-8, Japan
Research Site
Sagamihara-shi , 252-0, Japan
Research Site
Sakura-shi , 285-8, Japan
Research Site
Shinjuku-ku , 160-8, Japan
Research Site
Toon-shi , 791-0, Japan
Research Site
Yokohama-shi , 232-0, Japan
Research Site
Daegu , 41404, Korea, Republic of
Research Site
Goyang-si , 10408, Korea, Republic of
Research Site
Seoul , 03080, Korea, Republic of
Research Site
Seoul , 03722, Korea, Republic of
Research Site
Seoul , 05505, Korea, Republic of
Research Site
Seoul , 06591, Korea, Republic of
Research Site
Hilversum , 1213 , Netherlands
Research Site
Nijmegen , 6525 , Netherlands
Research Site
Tilburg , 5042 , Netherlands
Research Site
Bratislava , 851 0, Slovakia
Research Site
Presov , 08001, Slovakia
Research Site
Sala , 92701, Slovakia
Research Site
Trenčín , 911 0, Slovakia
Research Site
Barcelona , 08036, Spain
Research Site
Gerona , 17007, Spain
Research Site
Madrid , 08035, Spain
Research Site
Madrid , 28041, Spain
Research Site
Malaga , 29010, Spain
Research Site
Sevilla , 41009, Spain
Research Site
Adana , 01060, Turkey
Research Site
Ankara , 06590, Turkey
Research Site
Ankara , 06800, Turkey
Research Site
Istanbul , 34030, Turkey
Research Site
Izmir , 35360, Turkey
Research Site
Karsiyaka , 35575, Turkey
Research Site
Guildford , GU2 7, United Kingdom
Research Site
Manchester , M20 4, United Kingdom
Research Site
Sheffield , S10 2, United Kingdom
Research Site
Southampton , SO16 , United Kingdom
Research Site
Swansea , SA2 8, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 3

Estimated Enrollment:

895

Study ID:

NCT03732820

Recruitment Status:

Active, not recruiting

Sponsor:


AstraZeneca

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.